{"id":"zilovertamab","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02776917","NCT05406401","NCT05144841","NCT05139017","NCT06717347","NCT03833180","NCT04501939","NCT06890884","NCT05431179","NCT05458297","NCT06395103","NCT04504916","NCT05562830"],"aliases":["Cirmtuzumab","UC961"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Zilovertamab","companyId":"oncternal-therapeutics-inc","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Oncternal Therapeutics, Inc","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Zilovertamab","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02776917","phase":"Phase 1","title":"A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast","status":"COMPLETED","sponsor":"Barbara Parker, MD","isPivotal":false,"enrollment":23,"indication":"Breast Neoplasms","completionDate":"2024-02-26"},{"nctId":"NCT05406401","phase":"Phase 2","title":"A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":60,"indication":"Lymphoma, Large B-Cell, Diffuse (DLBCL)","completionDate":"2029-04-26"},{"nctId":"NCT05144841","phase":"Phase 2","title":"A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":140,"indication":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","completionDate":"2026-04-22"},{"nctId":"NCT05139017","phase":"Phase 2","title":"A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":290,"indication":"DLBCL, Diffuse Large B-Cell Lymphoma","completionDate":"2027-09-24"},{"nctId":"NCT06717347","phase":"Phase 3","title":"A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":1046,"indication":"Diffuse Large B-Cell Lymphoma","completionDate":"2032-03-29"},{"nctId":"NCT03833180","phase":"Phase 1","title":"A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)","status":"COMPLETED","sponsor":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","isPivotal":false,"enrollment":91,"indication":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","completionDate":"2023-12-18"},{"nctId":"NCT04501939","phase":"Phase 2","title":"Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","isPivotal":false,"enrollment":5,"indication":"Chronic Lymphocytic Leukemia","completionDate":"2026-07-22"},{"nctId":"NCT06890884","phase":"Phase 2","title":"A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participan","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":594,"indication":"Lymphoma, Large B-Cell, Diffuse","completionDate":"2032-12-16"},{"nctId":"NCT05431179","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantl","status":"WITHDRAWN","sponsor":"Oncternal Therapeutics, Inc","isPivotal":true,"enrollment":0,"indication":"Lymphoma, Mantle-Cell, Lymphoma","completionDate":"2026-12"},{"nctId":"NCT05458297","phase":"Phase 2","title":"A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (wav","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":223,"indication":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","completionDate":"2029-05-17"},{"nctId":"NCT06395103","phase":"Phase 1","title":"LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":90,"indication":"B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma","completionDate":"2029-03-31"},{"nctId":"NCT04504916","phase":"Phase 2","title":"A Phase 2 Study of VLS-101 in Patients With Solid Tumors","status":"TERMINATED","sponsor":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","isPivotal":false,"enrollment":102,"indication":"Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer","completionDate":"2023-06-12"},{"nctId":"NCT05562830","phase":"Phase 1","title":"A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Car","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":48,"indication":"Urothelial Carcinoma","completionDate":"2028-06-20"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":10,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}